UBS initiated coverage on ICON plc with a new price target
$ICLR
Biotechnology: Commercial Physical & Biological Resarch
Health Care
UBS initiated coverage of ICON plc with a rating of Buy and set a new price target of $270.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/24/2024 | $340.00 | Outperform → Neutral | Robert W. Baird |
| 10/14/2024 | Neutral | Redburn Atlantic | |
| 9/18/2024 | $379.00 | Outperform | Leerink Partners |
| 6/6/2024 | $370.00 | Buy | Goldman |
| 12/15/2023 | $357.00 | Buy | Truist |
| 9/13/2023 | $306.00 | Outperform | TD Cowen |
| 1/17/2023 | $215.00 → $260.00 | Equal Weight → Overweight | Barclays |
| 1/13/2023 | Equal Weight → Overweight | Barclays |
Robert W. Baird downgraded ICON plc from Outperform to Neutral and set a new price target of $340.00
Redburn Atlantic initiated coverage of ICON plc with a rating of Neutral
Leerink Partners initiated coverage of ICON plc with a rating of Outperform and set a new price target of $379.00
ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Nigel Clerkin as its new Chief Financial Officer (CFO). Nigel brings extensive experience and capability to the role of CFO. He commenced his career with KPMG, before joining Elan Corporation where he held a number of roles of increasing responsibility over a fifteen-year career, culminating in the role of group CFO in 2011, which he held until 2014. Nigel then moved to be CFO at ConvaTec, a global medical and technologies company, before becoming UDG Healthcare's CFO in 2018. During his tenure with UDG, he led substantial change and improvement programmes
SC 13G/A - ICON PLC (0001060955) (Subject)
SC 13G/A - ICON PLC (0001060955) (Subject)
SC 13G/A - ICON PLC (0001060955) (Subject)
Highlights Net business wins in the quarter of $2,328 million. Reflects a net book to bill in the quarter of 1.15, and a trailing twelve month net book to bill of 1.21. Closing backlog of $24.3 billion, an increase of 2.1% on quarter two 2024 and 9.4% on quarter three 2023. Quarter three revenue of $2,030.0 million. Quarter three adjusted EBITDA of $418.8 million or 20.6% of revenue. GAAP net income for the quarter of $197.1 million or $2.36 per diluted share, an increase of 19.8% on quarter three 2023 diluted earnings per share. Quarter three adjusted net income was $279.2 million or $3.35 per diluted share, an increase of 1.5% on quarter three 2023 adjusted diluted earnings
ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the third quarter 2024 after the market closes on Wednesday, October 23, 2024. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, October 24, 2024 at 8:00am ET. Any changes to this event and links to the live webcast will be posted on the Investor section of our website under "Events". A webcast replay of the conference call will be available approximately one hour following the conclusion of the call. About ICON plc ICON plc is a world-leading healthcare intelligen
Collaboration with industry partners critical to support effective translation of new therapeutic approaches to the clinic ICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced results from a recent survey of over 100 professionals engaged in oncology drug development to understand the current state of emerging oncology treatment development, including the associated clinical trial dynamics. Respondents acknowledged that much focus has been accorded to emerging oncology treatments; however, as of yet, there are varied views on the degree to which these precision approaches will improve patient outcomes. Significant inves
Icon (NASDAQ:ICLR) reported quarterly earnings of $3.75 per share which beat the analyst consensus estimate of $3.68 by 1.9 percent. The company reported quarterly sales of $2.12 billion which missed the analyst consensus estimate of $2.14 billion by 0.95 percent. This is a 4.95 percent increase over sales of $2.02 billion the same period last year.
Icon (NASDAQ:ICLR) has outperformed the market over the past 15 years by 7.5% on an annualized basis producing an average annual return of 19.57%. Currently, Icon has a market capitalization of $27.50 billion. Buying $100 In ICLR: If an investor had bought $100 of ICLR stock 15 years ago, it would be worth $1,480.44 today based on a price of $332.23 for ICLR at the time of writing. Icon's Performance Over Last 15 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by an
S-8 - ICON PLC (0001060955) (Filer)
6-K - ICON PLC (0001060955) (Filer)
6-K - ICON PLC (0001060955) (Filer)
Highlights Net business wins in the quarter of $2,328 million. Reflects a net book to bill in the quarter of 1.15, and a trailing twelve month net book to bill of 1.21. Closing backlog of $24.3 billion, an increase of 2.1% on quarter two 2024 and 9.4% on quarter three 2023. Quarter three revenue of $2,030.0 million. Quarter three adjusted EBITDA of $418.8 million or 20.6% of revenue. GAAP net income for the quarter of $197.1 million or $2.36 per diluted share, an increase of 19.8% on quarter three 2023 diluted earnings per share. Quarter three adjusted net income was $279.2 million or $3.35 per diluted share, an increase of 1.5% on quarter three 2023 adjusted diluted earnings
ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the third quarter 2024 after the market closes on Wednesday, October 23, 2024. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, October 24, 2024 at 8:00am ET. Any changes to this event and links to the live webcast will be posted on the Investor section of our website under "Events". A webcast replay of the conference call will be available approximately one hour following the conclusion of the call. About ICON plc ICON plc is a world-leading healthcare intelligen
Highlights Net business wins in the quarter of $2,579 million, an increase of 6.6% on quarter two 2023. Reflects a net book to bill in the quarter of 1.22, and a trailing twelve month net book to bill of 1.24. Closing backlog of $23.8 billion, an increase of 2.0% on quarter one 2024 and 9.9% on quarter two 2023. Quarter two revenue of $2,120.2 million representing an increase of 4.9% on prior year revenue and 5.3% on a constant currency basis. Quarter two adjusted EBITDA of $450.4 million or 21.2% of revenue, an increase of 8.7% on quarter two 2023. GAAP net income for the quarter of $146.9 million or $1.76 per diluted share, an increase of 25.7% on quarter two 2023 dilut